Trial Profile
Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Bitopertin (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TWILYTE
- Sponsors Roche
- 03 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Apr 2014 Status changed from completed to active, no longer recruiting.
- 23 Apr 2014 Status changed from active, no longer recruiting to completed.